,,iv  #aacth ,,congress  #b;d ,session  
,h4 ,,res4 #gji  ,,in ,,the ,,house ,,of
 ,,representatives  ,july #ca1 #bjad    
,mr4 ,vargas 7for himself1 ,mr4 ,rodney 
,davis of ,illinois1 ,mr4 ,denham1 ,mr4 
,honda1 ,mr4 ,rush1 and ,ms4 ,matsui7   
submitted the following resolution2     
which was referred to the ,committee on 
,energy and ,commerce  ,,resolution     
,recognizing the importance of          
transformative breakthroughs in         
biomedicine1 biotechnology1 and life    
sciences in the diagnosis1 management1  
curing1 and treatment of illness and the
 existence of a ,valley of ,death in    
biotechnology and life sciences funding 
that stifles innovation and impedes     
translational medical research4         
,whereas cancer1 rare and orphan        
diseases1 diabetes1 and ,alzheimer's are
 just a few of a growing number of      
large-scale challenges confronting      
modern society that can be addressed    
only through the sustained collaboration
 of thousands of highly skilled1        

dedicated1 and independent individuals  
over many years2 ,whereas many promising
 breakthroughs have occurred in         
biomedicine in recent years1 including  
gene therapies1 molecularly targeted    
drugs1 new modes of medical imaging and 
radiosurgery1 biomarkers for drug       
response1 human genome sequencing1 and  
advances in bioinformatics that enabled 
many of these new applications2 ,whereas
 biomedicine is far more advanced today 
than even a decade ago is indisputable1 
but breakthroughs require years of      
translational research at a cost of     
hundreds of millions of dollars and have
 a substantial likelihood of failure2   
,whereas the drug development pipeline  
is laden with unfavorable probabilities2
 ,whereas for every #e1jjj to #aj1jjj   
compounds that enter the drug discovery 
pipeline1 just #bej progress to         
preclinical development1 and only one   
will become an approved drug2 ,whereas  
the aggregate research and development  
budget of the pharmaceutical industry   

has nearly doubled from #fh1jjj1jjj1jjj 
in #bjjb to #abg1jjj1jjj1jjj in #bjaj1  
there has been little appreciable impact
 on the number of new drugs approved2   
,whereas ,congress must work in a       
bipartisan fashion to reform the ,food  
and ,drug ,administration's 7,,fda7     
review process for drug development and 
biomedical innovation in order to       
facilitate expeditious approval of safe 
and effective new products1 better      
outcomes for patients1 and more         
efficient and effective uses of ,,fda's 
limited resources2 ,whereas biomedical  
innovation has become much more         
challenging to finance with private and 
public equity2 ,whereas there is a      
growing concern within and outside the  
industry that the process of translating
 biomedical research into effective     
treatments is obsolete2 ,whereas biotech
 and life sciences traditional financing
 vehicles of private and public equity  
are becoming less effective funding     
sources because the needs and           

expectations of limited partners and    
shareholders are not consistent with the
 increasing complexity and risk of      
biomedical innovation2 ,whereas the     
lengthy process of biomedical innovation
 is becoming increasingly complex1      
expensive1 uncertain1 and fraught with  
conflicting motivations and             
public-policy implications2 ,whereas    
industry professionals frequently refer 
to the ,valley of ,death1 a steadily    
widening funding and resource gap that  
currently exists between basic research 
and clinical development1 effectively   
limiting the field of potential novel   
therapies1 technologies1 and treatments 
for patients2 ,whereas the life sciences
 industry needs novel approaches to     
early-stage drug development that better
 manage risk1 lower capital cost1       
improve research effectiveness1 create  
diverse portfolios1 leverage            
risk-tolerant capital1 and access new   
capital sources2 and ,whereas innovative
 financial structures can achieve the   

necessary grand scale of capital needed 
to support effective diversification of 
biotech investments and create stable   
and attractive investment opportunities 
along the development pipeline3 ,now1   
therefore1 be it  ,that the ,house of   
,representatives--  7#a7 recognizes the 
importance of transformative            
breakthroughs in biomedicine1           
biotechnology1 and life sciences in the 
diagnosis1 management1 curing1 and      
treatment of illness2  7#b7 recognizes  
the need for bipartisan reform of the   
,food and ,drug ,administration 7,,fda7 
in order to facilitate expeditious      
approval of safe and effective new      
products1 better outcomes for patients1 
and more efficient and effective uses of
 ,,fda's limited resources2  7#c7       
recognizes the existence of a ,valley of
 ,death in biomedicine1 biotechnology1  
and life sciences funding1 a steadily   
widening funding and resource gap that  
currently exists between basic research 
and clinical development1 effectively   

limiting the field of potential novel   
therapies and drugs for patients2 and   
7#d7 recognizes innovative financial    
structures can achieve the necessary    
grand scale of capital needed to support
 translational research and development 
in biomedicine1 biotechnology1 and life 
sciences4